Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias

2005, International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice, Fed. Regist, 70, 61134

2005, International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice, Fed. Regist, 70, 61133

10.1161/01.CIR.0000139333.83620.5D

Asakura, 2015, Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes, J Pharmacol. Toxicol. Methods, 75, 17, 10.1016/j.vascn.2015.04.002

10.1016/j.stem.2011.12.013

10.1001/jama.291.3.309

10.1093/toxsci/kfu084

Colatsky T. Fermini B. Gintant G. Pierson J. B. Sager P. Sekino Y. Strauss D. G. Stockbridge N. (2016). The comprehensive in vitro proarrhythmia assay (CiPA) initiative - update on progress. J. Pharmacol. Toxicol. Methods. , doi: 10.1016/j.vascn.2016.06.002.

10.1161/01.RES.77.5.950

Crumb W. J. Jr Vicente J. Johannesen L. Strauss D. G. (2016). An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel. J. Pharmacol. Toxicol. Methods.doi: 10.1016/j.vascn.2016.03.009.

10.1016/j.taap.2013.04.027

10.1177/1087057115594589

10.1177/0091270010381498

10.1046/j.1542-474X.2003.08413.x

10.1016/j.vascn.2014.09.005

Gilead Sciences (2013). I. Ranexa (Ranolazine), label information.

10.1093/toxsci/kfr158

10.1093/toxsci/kft205

10.1093/toxsci/kft113

Hernandez, 2016, Electrical stimulation promotes cardiac differentiation of human induced pluripotent stem cells, Stem Cells Int., 2016, 1718041., 10.1155/2016/1718041

Hoekstra, 2012, Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias, Front. Physiol, 3, 346., 10.3389/fphys.2012.00346

10.1002/cpt.205

10.1038/clpt.2014.155

10.1016/j.stem.2010.12.008

10.1089/scd.2009.0349

10.1161/CIRCRESAHA.112.300567

Kolb, 2008, Late dofetilide-associated life-threatening proarrhythmia, Int. J. Cardiol, 127, e54, 10.1016/j.ijcard.2007.04.014

Kramer, 2013, MICE models: Superior to the HERG model in predicting Torsade de Pointes, Sci. Rep., 3, 2100., 10.1038/srep02100

10.1124/jpet.104.073692

10.1038/nbt1327

10.1177/1087057114557232

10.1126/scitranslmed.3003623

10.1152/ajpheart.00694.2011

Maddah, 2015, A non-invasive platform for functional characterization of stem-cell-derived cardiomyocytes with applications in cardiotoxicity testing, Stem Cell Rep., 4, 621, 10.1016/j.stemcr.2015.02.007

Nagra, 2005, Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: A cautionary tale, J. Cardiovasc. Pharmacol. Ther., 10, 191, 10.1177/107424840501000307

Navarrete, 2013, Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays, Circulation, 128(11 Suppl 1), S3, 10.1161/CIRCULATIONAHA.112.000570

Pfizer (1999). Tikosyn (Dofetilide), label information.

Pharm. Res. Assoc. (1999). Cardioquin (Quinidine Polygalacturonate), label information.

10.1016/S0008-6363(02)00846-5

10.1111/j.1540-8159.2005.00179.x

10.1016/j.ahj.2013.11.004

10.1007/s40264-013-0016-z

10.1016/j.cell.2007.11.019

10.1016/j.cell.2006.07.024

Talajic, 1987, Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: Evidence for clinically relevant activity of the metabolite, Circulation, 75, 265, 10.1161/01.CIR.75.1.265

10.1128/AAC.06396-11

10.1038/nature06894

10.1161/CIRCULATIONAHA.113.007765